Pharmadrug Inc.
PHRX
CNSX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 261.64% | -162.93% | |||
| Depreciation & Amortization | -2.22% | -2.17% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -49.53% | 73.05% | |||
| Operating Income | 49.53% | -73.05% | |||
| Income Before Tax | -1,532.00% | 96.23% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1,532.00% | 96.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -79.33% | -- | |||
| Net Income | -234.23% | 139.19% | |||
| EBIT | 49.53% | -73.05% | |||
| EBITDA | 57.25% | -97.85% | |||
| EPS Basic | -220.00% | 138.46% | |||
| Normalized Basic EPS | -500.00% | 114.29% | |||
| EPS Diluted | -220.00% | 138.46% | |||
| Normalized Diluted EPS | -500.00% | 114.29% | |||
| Average Basic Shares Outstanding | 4.33% | -0.81% | |||
| Average Diluted Shares Outstanding | 4.33% | -0.81% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||